Live Breaking News & Updates on Treatment Failure Criteria

Stay updated with breaking news from Treatment failure criteria. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

Experts discuss the impact of elacestrant on patient well-being, including potential cardiovascular and gastrointestinal toxicities, quality of life, and patient feedback regarding access to treatment. ....

William Gradishar , Gregory Vidal , Rena Callahan , Mabel Mardones , Peer Exchange , European Society For Medical Oncology Congress , Medical Oncology Congress , Oral Serd , Metastatic Breast Cancer , Therapeutic Advances , Panel Discussion , Her Positive , Her2 Negative , Selective Estrogen Receptor Degrader , Endocrine Therapy , Targeted Therapy , Treatment Developments , Medical Oncology , Breast Oncology , Breast Cancer , Clinical Guidelines , Fda Label , Nccn Guidelines , Esr1 Mutations , Treatment Resistance , Moral Therapy ,

Elacestrant: Treatment Considerations, Including Dosing and Compliance

Experts explore treatment considerations when treating patients with metastatic breast cancer with elacestrant, including dosing, patient selection, adherence, and treatment duration. Participants also discuss dose modifications, adherence concerns, and how they determine treatment failure. ....

William Gradishar , Mabel Mardones , Rena Callahan , Gregory Vidal , Peer Exchange , Oral Serd , Metastatic Breast Cancer , Therapeutic Advances , Panel Discussion , Her Positive , Her2 Negative , Selective Estrogen Receptor Degrader , Endocrine Therapy , Targeted Therapy , Treatment Developments , Medical Oncology , Breast Oncology , Breast Cancer , Clinical Guidelines , Fda Label , Nccn Guidelines , Esr1 Mutations , Treatment Resistance , Moral Therapy , Disease Progression , Patient Profiles ,

Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity. ....

Rena Callahan , William Gradishar , Mabel Mardones , Gregory Vidal , Peer Exchange , Oral Serd , Metastatic Breast Cancer , Therapeutic Advances , Panel Discussion , Her Positive , Her2 Negative , Selective Estrogen Receptor Degrader , Endocrine Therapy , Targeted Therapy , Treatment Developments , Medical Oncology , Breast Oncology , Breast Cancer , Clinical Guidelines , Fda Label , Nccn Guidelines , Esr1 Mutations , Treatment Resistance , Moral Therapy , Disease Progression , Patient Profiles ,

ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection. ....

William Gradishar , Rena Callahan , Mabel Mardones , Gregory Vidal , Peer Exchange , Oral Serd , Metastatic Breast Cancer , Therapeutic Advances , Panel Discussion , Her Positive , Her2 Negative , Selective Estrogen Receptor Degrader , Endocrine Therapy , Targeted Therapy , Treatment Developments , Medical Oncology , Breast Oncology , Breast Cancer , Clinical Guidelines , Fda Label , Nccn Guidelines , Esr1 Mutations , Treatment Resistance , Moral Therapy , Disease Progression , Patient Profiles ,

Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

Experts discuss how they determine whether a patient with metastatic breast cancer is a candidate for treatment with elacestrant based on FDA approved indication, NCCN guidelines, and the results of ESR1 mutation and resistance marker testing. Participants also discuss how they determine treatment failure or resistance. ....

Breast Cancer , Clinical Guidelines , Oral Serd , Metastatic Breast Cancer , Therapeutic Advances , Panel Discussion , Her Positive , Her2 Negative , Selective Estrogen Receptor Degrader , Endocrine Therapy , Targeted Therapy , Treatment Developments , Medical Oncology , Breast Oncology , Fda Label , Nccn Guidelines , Esr1 Mutations , Treatment Resistance , Moral Therapy , Disease Progression , Patient Profiles , Precision Medicine , Metastatic Cancer , Treatment Sequencing , Liquid Biopsy Tissue Testing , Precision Oncology ,